嗜酸性肉芽肿放疗疗效及复发的影响因素分析  

An analysis of the impact factors of treatment efficiency and recurrence of eosinophilic granuloma after radiotherapy

作　　者：毕建强[1] 曹永珍[1] 吕仲虹[1] 杨天恩[1] 

机构地区：[1]天津医科大学总医院放疗科,天津300052

出　　处：《天津医科大学学报》2008年第4期532-535,共4页Journal of Tianjin Medical University

摘　　要：目的:探讨影响嗜酸性肉芽肿放射治疗后复发的因素,以进一步指导临床治疗。方法:回顾分析1987～2006年间收治的32例嗜酸性肉芽肿患者,其中手术切除合并放射治疗12例,单纯放疗20例,通过对32例患者的病例资料及随访结果的研究,分析影响嗜酸性肉芽肿放疗后复发的因素。结果:初次治疗达到完全缓解的22例,占68.75%;部分缓解5例,占15.63%;无变化4例,占12.5%;进展1例。截止到随访日期,32例患者中放射治疗后复发13例。放疗大于20 Gy的患者与小于20 Gy的患者间差别无统计学意义。单因素分析结果显示疼痛和初治疗效是嗜酸性肉芽肿放疗后复发的影响因素,多因素分析并未发现嗜酸性肉芽肿复发的独立影响因素。结论:放疗剂量的提高并不能更好的抑制复发,对于初次放疗的患者应尽量争取达到完全缓解。初治疗效是否影响嗜酸性肉芽肿的复发值得进一步研究。Objective： To investigate the impact factors of eosinophilic granuloma recurrence after radiotherapy. Methods：A retrospective analysis of 32 patients of eosinophilic granuloma, in which 12 cases were treated by surgical resection combined with radiotherapy, 20 cases were treated by radiotherapy alone. Reviewing the clinical data and the follow-up results of 32 patients, we analyzed the impact factors of the recurrence of eosinophilic granuloma after radiotherapy. Results：In initial results, 22 cases achieved complete remission, accounting for 68.75%; 5 cases achieved partial remission, accounting for 15.63 percent; 4 cases had no change, accounting for 12.5%; 1 case in progress. As of the cutoff date for this study, 13 patients were relapsed after radiotherapy. Univariate analysis showed that pain and initial treatment efficiency were influencing factors of the recurrence of eosinophilic granuloma after radiotherapy, however they were not influencing factors on multivariate analysis. Conclusion： Enhancing radiotherapic dose can not effectively inhibit the recurrence of EG. Patients receiving initial radiotherapy should achieve complete remission as far as possible. As for influencing factors of the recurrence of eosinophilic granuloma after radiotherapy, treatment efficiency is worth to exploring fourthly.

关 键 词：嗜酸性肉芽肿 放射治疗 复发 初治疗效 疼痛 

分 类 号：Q730.55[生物学—分子生物学] R738[医药卫生—肿瘤]